MCID: MLG069
MIFTS: 46

Malignant Hypertension

Categories: Cardiovascular diseases, Genetic diseases, Blood diseases, Rare diseases

Aliases & Classifications for Malignant Hypertension

MalaCards integrated aliases for Malignant Hypertension:

Name: Malignant Hypertension 12 14 69
Hypertension, Malignant 42
Hypertension Malignant 52

Classifications:



External Ids:

Disease Ontology 12 DOID:10824
MeSH 42 D006974
NCIt 47 C3118
UMLS 69 C0020540

Summaries for Malignant Hypertension

MalaCards based summary : Malignant Hypertension, also known as hypertension, malignant, is related to antiphospholipid syndrome and pyelonephritis. An important gene associated with Malignant Hypertension is REN (Renin), and among its related pathways/superpathways are p70S6K Signaling and Peptide hormone metabolism. The drugs Cisplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and colon, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Malignant Hypertension

Diseases in the Familial Hypertension family:

Hypertension, Essential Hypertension, Essential 7
Hypertension, Essential 8 Malignant Essential Hypertension
Malignant Hypertension Benign Essential Hypertension
Benign Secondary Hypertension Malignant Secondary Hypertension

Diseases related to Malignant Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
id Related Disease Score Top Affiliating Genes
1 antiphospholipid syndrome 29.4 EDN1 REN
2 pyelonephritis 29.3 ACE EDN1 REN
3 malignant hypertensive renal disease 11.8
4 malignant renovascular hypertension 10.8
5 malignant secondary hypertension 10.8
6 malignant essential hypertension 10.8
7 hemolytic uremic syndrome, atypical 1 10.7
8 hypothyroidism due to iodide transport defect 10.6 ACE REN
9 primary hyperoxaluria 10.6 ACE REN
10 mody, type ii 10.6 ACE REN
11 listeriosis 10.6 ACE REN
12 non-congenital cyst of kidney 10.5 ACE REN
13 voyeurism 10.5 ACE REN
14 pulmonary valve insufficiency 10.4 ACE REN
15 epithelial predominant pulmonary blastoma 10.4 ACE NPPA
16 repetitive stress injuries 10.4 NPPA REN
17 microphthalmia, isolated, with coloboma 7 10.4 ACE REN
18 cystic fibrosis and congenital absence of the vas deferens 10.4 AGTR1 REN
19 synovial chondromatosis 10.3 ACE NPPA
20 pelizaeus-merzbacher-like disease 10.3 ACE AGT
21 suppurative otitis media 10.3 ACE NPPA
22 adams-oliver syndrome 5 10.2 ACE REN
23 hypoaldosteronism, congenital, due to cmo ii deficiency 10.2 AGT REN
24 urinary bladder posterior wall cancer 10.2 NPPA REN
25 atrial septal defect 7, with or without av conduction defects 10.1 ACE NPPA REN
26 hypodontia of incisors and premolars 10.1 ACE NPPA REN
27 familial isolated pituitary adenoma 10.1 AGT AGTR1
28 uterine inflammatory disease 10.1 EDN1 REN
29 pyogenic arthritis, pyoderma gangrenosum and acne 10.1 ACE NPPA REN
30 prostate neuroendocrine neoplasm 10.1 ACE AGTR1 REN
31 hepatic infarction 10.1 EDN1 REN
32 mental retardation cataracts calcified pinnae myopathy 10.1 AGT AGTR1
33 hypertrichosis of eyelid 10.1 ACE ADAMTS13 AGTR1
34 spondyloepimetaphyseal dysplasia, faden-alkuraya type 10.0 AGT REN
35 pediatric angiosarcoma 10.0 ACE REN
36 acute liver failure 10.0 ADAMTS13 NPPA REN
37 munchausen by proxy 10.0 ACE EDN1
38 stroke, ischemic 10.0 ACE AGTR1 REN
39 cystinosis 10.0 ACE AGT REN
40 eustachian tube disease 10.0 EDN1 REN
41 cervix uteri carcinoma in situ 9.9 ACE AGT REN
42 capillary hemangioma 9.9 EDN1 REN
43 encephalopathy 9.9
44 panuveitis 9.9 AGTR1 NPPA REN
45 hypertensive retinopathy 9.9
46 hypertensive encephalopathy 9.9
47 blackwater fever 9.9 EDN1 NPPA
48 cataract, autosomal dominant congenital 4 9.9 ACE AGT AGTR1
49 potato nose 9.9 ACE AGT AGTR1
50 trichinosis 9.8 ACE AGT AGTR1

Graphical network of the top 20 diseases related to Malignant Hypertension:



Diseases related to Malignant Hypertension

Symptoms & Phenotypes for Malignant Hypertension

MGI Mouse Phenotypes related to Malignant Hypertension:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.95 ACE ADM AGT AGTR1 EDN1 NPPA
2 homeostasis/metabolism MP:0005376 9.92 ACE ADAMTS13 ADM AGT AGTR1 EDN1
3 hematopoietic system MP:0005397 9.85 ACE ADAMTS13 ADM AGTR1 NPPA REN
4 immune system MP:0005387 9.73 ACE ADAMTS13 ADM AGT AGTR1 REN
5 mortality/aging MP:0010768 9.7 ACE ADAMTS13 ADM AGT AGTR1 EDN1
6 muscle MP:0005369 9.35 ADM AGT EDN1 NPPA REN
7 renal/urinary system MP:0005367 9.17 ACE ADM AGT AGTR1 EDN1 NPPA

Drugs & Therapeutics for Malignant Hypertension

Drugs for Malignant Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Paclitaxel Approved, Vet_approved Phase 2, Phase 3 33069-62-4 36314
4 Atorvastatin Calcium Phase 3 134523-03-8
5 Antimetabolites Phase 2, Phase 3
6 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
7 Albumin-Bound Paclitaxel Phase 2, Phase 3
8 Antimetabolites, Antineoplastic Phase 2, Phase 3
9 Antimitotic Agents Phase 2, Phase 3
10 Antineoplastic Agents, Phytogenic Phase 2, Phase 3
11
s 1 (combination) Phase 2, Phase 3
12
Diazoxide Approved Phase 2 364-98-7 3019
13
Bevacizumab Approved, Investigational Phase 2 216974-75-3
14
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
15
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
17
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
18
Enalapril Approved, Vet_approved Phase 2 75847-73-3 5362032 40466924
19
Enalaprilat Approved Phase 2 76420-72-9 6917719
20
Propranolol Approved, Investigational Phase 2 525-66-6 4946
21
Choline Approved, Nutraceutical Phase 2 62-49-7 305
22 Antihypertensive Agents Phase 2
23 Gastrointestinal Agents Phase 2
24 Hypolipidemic Agents Phase 2
25 Lipid Regulating Agents Phase 2
26 Nootropic Agents Phase 2
27 Vasodilator Agents Phase 2
28 Angiogenesis Inhibitors Phase 2
29 Angiogenesis Modulating Agents Phase 2
30 Antibodies Phase 2
31 Antibodies, Monoclonal Phase 2
32 Immunoglobulins Phase 2
33 Anti-Bacterial Agents Phase 1, Phase 2
34 Antibiotics, Antitubercular Phase 1, Phase 2
35 Antifungal Agents Phase 1, Phase 2
36 Anti-Infective Agents Phase 1, Phase 2
37 Adrenergic Agents Phase 2
38 Adrenergic Antagonists Phase 2
39 Adrenergic beta-Antagonists Phase 2
40 Angiotensin-Converting Enzyme Inhibitors Phase 2
41 Anti-Arrhythmia Agents Phase 2
42 HIV Protease Inhibitors Phase 2
43 Neurotransmitter Agents Phase 2
44
protease inhibitors Phase 2
45
Salmon Calcitonin Approved, Investigational 47931-85-1 16129616
46
Glycerol Approved, Investigational 56-81-5 753
47
Lidocaine Approved, Vet_approved 137-58-6 3676
48
Mannitol Approved, Investigational 69-65-8 453 6251
49 Bone Density Conservation Agents
50 calcitonin

Interventional clinical trials:

(show all 21)

id Name Status NCT ID Phase Drugs
1 Stenting in Renal Dysfunction Caused by Atherosclerotic Renal Artery Stenosis Completed NCT00150943 Phase 3
2 Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer Terminated NCT01704690 Phase 2, Phase 3 S-1 and Paclitaxel;Paclitaxel and Cisplatin;5-FU and Cisplatin
3 Diazoxide Choline in Hypertriglyceridemia Completed NCT00696475 Phase 2 Diazoxide choline;Diazoxide choline;Diazoxide choline;Placebo
4 AMG 102 and Avastin for Recurrent Malignant Glioma Completed NCT01113398 Phase 2 AMG 102;Avastin
5 Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Completed NCT00286156 Phase 1, Phase 2 Rapamune
6 Bevacizumab vs Dacarbazine in Metastatic Melanoma Terminated NCT01705392 Phase 2 Bevacizumab;Propranolol;Enalapril;Dacarbazine
7 Single Incision Laparoscopy Completed NCT00616616
8 Assessing Blood Pressure Remotely in Childhood Cancer Survivors Completed NCT02476162
9 Investigation of Waist Circumference and Waist/Hip Ratio as a Predictive Risk Factor for Morbidity and Mortality After Colorectal Surgery Completed NCT01737515
10 Thyrotropin Over-suppression and Heart Completed NCT02645786
11 Non Invasive Measurements of Intracranial Pressure in Patients With Malignant Glioma Recruiting NCT02520492
12 Zonulo-hyaloido-vitrectomy for Malignant Glaucoma Recruiting NCT02613143
13 Stereotactic Infarct Tissue Aspiration for Malignant Infarction of Middle Cerebral Artery Recruiting NCT02609256
14 Evaluation of Complex Renal Cyst With CEUS/Functional MRI Versus CT Recruiting NCT02371551
15 Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma Active, not recruiting NCT01810744
16 Non-invasive Absolute Intracranial Pressure Measurement in Patients With Malignant Middle Cerebral Artery Infarction for Determination of Timing to Descompressive Craniectomy. Not yet recruiting NCT03221959
17 Evaluation of Different Etiologies of Obscure Ascites Not yet recruiting NCT03205748
18 Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer Not yet recruiting NCT03006289
19 Endoscopic Access Loop With Bilio-enteric Anastomosis: A Prospective Randomized Comparison Between Gastric and Subcutaneous Accesses Not yet recruiting NCT03252379
20 Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor Terminated NCT01096381
21 Disc Edema in Patients With Chronic Kidney Disease Withdrawn NCT00769834

Search NIH Clinical Center for Malignant Hypertension

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hypertension, malignant

Genetic Tests for Malignant Hypertension

Anatomical Context for Malignant Hypertension

MalaCards organs/tissues related to Malignant Hypertension:

39
Kidney, Heart, Colon, Bone, Brain, Thyroid, Liver

Publications for Malignant Hypertension

Articles related to Malignant Hypertension:

(show top 50) (show all 561)
id Title Authors Year
1
Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. ( 28356668 )
2017
2
Malignant Hypertension Revisited-Does This Still Exist? ( 28200072 )
2017
3
Thrombotic microangiopathy due to malignant hypertension complicated with late-onset bleeding after renal biopsy. ( 28679995 )
2017
4
Orbital haematoma in malignant hypertension. ( 28173968 )
2017
5
Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry. ( 28622157 )
2017
6
Malignant hypertension as a rare cause of thrombotic microangiopathy. ( 28596204 )
2017
7
Malignant Hypertensive Retinopathy in an Infant with Mid-Aortic Occlusion. ( 27795862 )
2016
8
Idiopathic midaortic syndrome with malignant hypertension in 3-year-old boy. ( 28018454 )
2016
9
An unusual cause of malignant hypertension in young. ( 27728492 )
2016
10
Malignant Hypertension with Thrombotic Microangiopathy. ( 27523008 )
2016
11
The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. ( 26778772 )
2016
12
Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats. ( 27428043 )
2016
13
Malignant hypertension: new aspects of an old clinical entity. ( 26658350 )
2016
14
CD4(+)CD25(+) T Cells in primary malignant hypertension related kidney injury. ( 27278520 )
2016
15
Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. ( 26833491 )
2016
16
A case report of malignant hypertension in a young woman. ( 27389397 )
2016
17
First reported case of khat cardiomyopathy and malignant hypertension in Australia. ( 27981767 )
2016
18
[OP.LB.02.05] A PATIENT WITH MALIGNANT HYPERTENSION SUCCESSFULLY TREATED WITH ECULIZUMAB AND BOSENTAN - SUGGESTIONS OF SIGNIFICANT INTERACTIONS OF COMPLEMENT AND THE ENDOTHELIN SYSTEM IN BLOOD PRESSURE CONTROL. ( 27508801 )
2016
19
Brain Natriuretic Peptide Counteracting the Renin-angiotensin-aldosterone System in Accelerated Malignant Hypertension. ( 27865304 )
2016
20
A global amnesia associated with the specific variant of posterior reversible encephalopathy syndrome (PRES) that developed due to severe preeclampsia and malignant hypertension. ( 27099774 )
2016
21
Takayasu arteritis presenting with malignant hypertension; a rare manifestation of a rare disease: a case report and review of the literature. ( 27216226 )
2016
22
Posterior reversible encephalopathy syndrome in malignant hypertension secondary to focal segmental glomerulosclerosis. ( 27535734 )
2016
23
IMAGES IN CLINICAL MEDICINE. Reversible Loss of Vision in Malignant Hypertension. ( 27050208 )
2016
24
SPONTANEOUS BILATERAL HEMORRHAGIC CHOROIDAL DETACHMENTS ASSOCIATED WITH MALIGNANT HYPERTENSION. ( 27177073 )
2016
25
An ectopic renin-secreting adrenal corticoadenoma in a child with malignant hypertension. ( 26997629 )
2016
26
Fenofibrate Attenuates Malignant Hypertension by Suppression of the Renin-angiotensin System: A Study in Cyp1a1-Ren-2 Transgenic Rats. ( 27916218 )
2016
27
Malignant hypertension-associated thrombotic microangiopathy following cocaine use. ( 26787585 )
2016
28
Basal transethmoidal encephalocele and malignant hypertension in a parturient with a seizure disorder. A case report. ( 25745752 )
2015
29
Malignant Hypertension and Thrombotic Thrombocytopenic Purpura: False Friends. ( 26083445 )
2015
30
From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. ( 26582411 )
2015
31
Does Anticomplement Therapy Have a Role in the Management of Malignant Hypertension? ( 26359936 )
2015
32
Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. ( 26137201 )
2015
33
Bilateral exudative retinal detachment with choroidopathy in malignant hypertension. ( 27132968 )
2015
34
Malignant hypertensive retinopathy as a presenting sign of an occult dead fetus. ( 26082609 )
2015
35
Increasing trend in admissions for malignant hypertension and hypertensive encephalopathy in the United States. ( 25801877 )
2015
36
Characteristics of podocyte injury in malignant hypertensive nephropathy of rats (MSHRSP/Kpo strain). ( 26522148 )
2015
37
Malignant hypertension in lgA nephropathy. ( 25761814 )
2015
38
Severe visual loss caused by unrecognized malignant hypertension in a 15-year-old girl. ( 25868960 )
2015
39
Malignant Hypertension: Clinical Manifestations of 7 Cases. ( 25902134 )
2015
40
Tremendous result of bevacizumab in malignant hypertensive retinopathy. ( 25709280 )
2015
41
Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis. ( 25611832 )
2015
42
Candida-associated pseudo-aneurysm of the transplant renal artery presenting as malignant hypertension and managed successfully without nephrectomy. ( 26354578 )
2015
43
Malignant hypertension and retinopathy in a western lowland gorilla (Gorilla gorilla gorilla). ( 24646309 )
2014
44
Inflammatory optic disc edema due to Sarcoidosis mimicking malignant hypertension. ( 25351429 )
2014
45
Use of a pulsatile perfusion pump for renal autotransplantation in a patient undergoing thoracoabdominal bypass for malignant hypertension secondary to Takayasu arteritis. ( 24698771 )
2014
46
Malignant hypertension with thrombotic microangiopathy and persistent acute kidney injury (AKI). ( 25503954 )
2014
47
Adaptive optics assisted visualization of thickened retinal arterial wall in a patient with controlled malignant hypertension. ( 25336903 )
2014
48
Comment on: Malignant hypertension and nephrotic range proteinuria without hematuria: IgA nephropathy. ( 25120304 )
2014
49
An 18-year-old female patient with malignant hypertension masked as thrombotic thrombocytopenia purpura? ( 24832123 )
2014
50
Renal fibromuscular dysplasia with malignant hypertension cured by balloon angioplasty with stenting. ( 24927042 )
2014

Variations for Malignant Hypertension

Expression for Malignant Hypertension

Search GEO for disease gene expression data for Malignant Hypertension.

Pathways for Malignant Hypertension

GO Terms for Malignant Hypertension

Cellular components related to Malignant Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ACE ADAMTS13 ADM AGT EDN1 NPPA
2 extracellular space GO:0005615 9.17 ACE ADAMTS13 ADM AGT EDN1 NPPA

Biological processes related to Malignant Hypertension according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.85 ADM AGT EDN1
2 response to lipopolysaccharide GO:0032496 9.82 ADM EDN1 REN
3 response to hypoxia GO:0001666 9.82 ADM EDN1 NPPA
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.76 ADM AGT AGTR1 EDN1
5 female pregnancy GO:0007565 9.72 ADM AGT NPPA
6 kidney development GO:0001822 9.71 ACE AGT AGTR1 REN
7 cellular response to interferon-gamma GO:0071346 9.68 ADAMTS13 EDN1
8 regulation of cardiac conduction GO:1903779 9.68 AGT NPPA
9 calcium-mediated signaling GO:0019722 9.68 AGTR1 EDN1
10 positive regulation of endothelial cell migration GO:0010595 9.67 AGT EDN1
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 AGT EDN1
12 positive regulation of protein tyrosine kinase activity GO:0061098 9.66 ACE AGT
13 blood vessel remodeling GO:0001974 9.66 ACE AGT
14 positive regulation of reactive oxygen species metabolic process GO:2000379 9.65 AGT AGTR1
15 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway GO:0051482 9.65 AGTR1 EDN1
16 positive regulation of cardiac muscle hypertrophy GO:0010613 9.64 AGT EDN1
17 vasoconstriction GO:0042310 9.63 AGT EDN1
18 peptide catabolic process GO:0043171 9.63 ACE ADAMTS13
19 positive regulation of cellular protein metabolic process GO:0032270 9.62 AGT AGTR1
20 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.62 AGT AGTR1
21 response to muscle stretch GO:0035994 9.61 EDN1 NPPA
22 cell growth involved in cardiac muscle cell development GO:0061049 9.61 AGT NPPA
23 positive regulation of heart rate GO:0010460 9.61 ADM EDN1 NPPA
24 beta-amyloid metabolic process GO:0050435 9.6 ACE REN
25 regulation of blood vessel diameter GO:0097746 9.59 ACE AGTR1
26 low-density lipoprotein particle remodeling GO:0034374 9.58 AGT AGTR1
27 positive regulation of renal sodium excretion GO:0035815 9.58 AGT EDN1
28 artery smooth muscle contraction GO:0014824 9.57 AGT EDN1
29 positive regulation of cholesterol esterification GO:0010873 9.56 AGT AGTR1
30 positive regulation of NAD(P)H oxidase activity GO:0033864 9.54 AGT AGTR1
31 regulation of blood vessel size GO:0050880 9.54 AGT EDN1 NPPA
32 regulation of renal sodium excretion GO:0035813 9.52 AGT AGTR1
33 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.51 AGT AGTR1
34 angiotensin maturation GO:0002003 9.5 ACE AGT REN
35 regulation of blood volume by renin-angiotensin GO:0002016 9.49 AGT REN
36 regulation of renal output by angiotensin GO:0002019 9.48 ACE AGT
37 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.43 ACE AGT AGTR1
38 renin-angiotensin regulation of aldosterone production GO:0002018 9.33 AGT AGTR1 REN
39 regulation of vasoconstriction GO:0019229 9.26 ACE AGT AGTR1 EDN1
40 regulation of blood pressure GO:0008217 9.02 ACE AGT EDN1 NPPA REN

Molecular functions related to Malignant Hypertension according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.46 ADM EDN1 NPPA REN
2 bradykinin receptor binding GO:0031711 8.96 ACE AGTR1
3 hormone activity GO:0005179 8.92 ADM AGT EDN1 NPPA

Sources for Malignant Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....